Skip to main content

Incomplete Microscopic Colitis

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Dr. Falk Pharma
Dr. Falk PharmaGermany - Freiburg
1 program
1
Budesonide granules 9 mgPhase 31 trial
Active Trials
NCT02142634Completed44Est. Feb 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dr. Falk PharmaBudesonide granules 9 mg

Clinical Trials (1)

Total enrollment: 44 patients across 1 trials

NCT02142634Dr. Falk PharmaBudesonide granules 9 mg

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Start: May 2014Est. completion: Feb 202044 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.